Ignite Creation Date:
2024-05-06 @ 3:49 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04777851
Status:
RECRUITING
Last Update Posted:
2024-07-12
First Post:
2021-02-25
Brief Title:
Regorafenib-pembrolizumab vs TACETARE in Intermediate Stage HCC Beyond Up-to-7
Sponsor:
Translational Research in Oncology
Organization:
Translational Research in Oncology
Organization Data
Organization:
Translational Research in Oncology
Class:
OTHER
Study ID:
TRIO041
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Translational Research in Oncology
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Bayer | INDUSTRY |